M.R. Migliorino - Concepedia

Author

M.R. Migliorino

Also Known As

M Migliorino, M R Migliorino, M. Migliorino, M. R. Migliorino, M. Rita Migliorino, M.-R. Migliorino, M.R. Migliorino, M.Rita Migliorino, Marta Rita Migliorino

Publications

Citations

H-Index

Concepts

All Affiliations

Carlo Forlanini Hospital Azienda Ospedaliera San Camillo-Forlanini Roche (Switzerland)Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Istituti di Ricovero e Cura a Carattere Scientifico

About

M.R. Migliorino is an author at Carlo Forlanini Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	315
2	Health Sciences	2	2	24
3	Pathology	2	2	37
4	Geriatrics	1	1	86
5	Neurology	1	1	19

M.R. Migliorino

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial C. Gridelli, Federica Perrone, Ciro Gallo, JNCI Journal of the National Cancer Institute	2003	795
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study Silvia Novello, Julien Mazières, In‐Jae Oh, Annals of Oncology	2018	336
Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, New England Journal of Medicine	2024	320
Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy Andrea Mancuso, M.R. Migliorino, Stefano De Santis, Annals of Oncology Geriatric OncologyAgingFunctional/cognitive CapacityGeriatricsMedicine	2005	86
LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC) Benjamin Solomon, Jin Seok Ahn, Rafał Dziadziuszko, Annals of Oncology OncologyPharmacologyImmune Checkpoint InhibitorCancer TreatmentLba2 Alina	2023	71
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer Jennifer Moriatis Wolf, Åslaug Helland, In‐Jae Oh, ESMO Open	2022	48
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes Alessio Cortellini, Alessandro Leonetti, Annamaria Catino, Clinical & Translational Oncology SclerostinDisease ProgressionClinical TrialsMulticenter StudyMedicine	2019	28
A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer M.R. Migliorino, Filippo de Marinis, Fabrizio Nelli, Lung Cancer OncologyBronchial Neoplasm3-Week ScheduleCancer TreatmentMedicine	2002	26
IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC Mark A. Socinski, Achim Rittmeyer, D. Shapovalov, Annals of Oncology Progression-free SurvivalSquamous NsclcMedicinePharmacologyImmune Checkpoint Inhibitor	2018	26
Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC) Silvia Novello, Julien Mazières, In‐Jae Oh, Annals of Oncology MedicinePrimary ResultsAlectinib Versus ChemotherapyPathologyImmune Checkpoint Inhibitor	2017	23

Page 1